Phase I Study: Ivosidenib (AG-120) in Mutant IDH1 Acute Myeloid Leukemia and Other Advanced Hematologic Malignancies
Source: 2017 American Society of Hematology Annual Meeting*

Conference Program

 

Slideset

Phase I Study: Ivosidenib (AG-120) in Mutant IDH1 Acute Myeloid Leukemia and Other Advanced Hematologic Malignancies

Ivosidenib, an investigational mutant IDH1 inhibitor, was well tolerated with evidence of activity and durable responses in patients with malignancies harboring mutated IDH1.
Format: Microsoft PowerPoint (.ppt)
File size: 269 KB
Date posted: 12/20/2017